Foundayo, an Ozempic-style GLP-1 pill, has been approved in Australia to assist with weight loss and treat type 2 diabetes, with the daily medicine expected to become available within days.
The Therapeutic Goods Administration cleared the treatment on Tuesday, allowing it to be prescribed privately. It has not yet been added to the Pharmaceutical Benefits Scheme.
Made by US pharmaceutical company Eli Lilly, Foundayo is a small-molecule GLP-1 that mimics a natural hormone involved in controlling hunger and slowing digestion. Unlike existing treatments, it can be taken at any time of day without restrictions on food or water.
Associate Professor Samantha Hocking, president of the National Association of Clinical Obesity Services, said the decision could help address Australia’s obesity rates.
“Australia is grappling with rising rates of overweight and obesity, which now affect around 13 million adults,” she said.
“Obesity is a complex chronic disease that increases the risk of at least 30 other serious medical conditions, ranging from cancer and cardiovascular disease to type 2 diabetes.
“The impact of obesity and type 2 diabetes on individuals, families and our health system highlights the urgent need for stronger prevention efforts and improved access to clinically proven treatment options.”
Eli Lilly Australia general manager Dr Manny Simons said the approval followed more than a decade of research. Clinical trials involved more than 10,000 patients across 15 countries, including partnerships with 12 Australian hospitals and clinics.
“Now that Foundayo can be prescribed, our focus is on ways to deliver broader access for Australians who may benefit from this new medicine,” Dr Simons said.
The company said Foundayo should not be used alongside other GLP-1 medicines. The most common side effects affect the digestive system and were mostly mild or moderate in clinical trials, particularly while doses were being increased.
Lilly also warned of low blood sugar when Foundayo is used with insulin or a sulfonylurea, as well as the risk of pancreatitis. The medicine should not be used during pregnancy or by people who are hypersensitive to orforglipron or any of its ingredients, and some medicines may interact with it.
Foundayo is the latest GLP-1 pill to be approved by the TGA, following Wegovy’s clearance several weeks ago.
